Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4068050 | 0.85 | HTT (0.58) | KMT2AGAAALDH1A1HPGDKDM4E | |
| SCHEMBL4073041 | 0.82 | ALDH1A1 (0.62) | KMT2AGAAALDH1A1HPGDLMNA | |
| SCHEMBL2017132 | 0.78 | ALDH1A1 (0.73) | KMT2AGAAALDH1A1HPGDKDM4E | |
| SCHEMBL9113880 | 0.78 | KMT2A (1.00) | KMT2AGAAALDH1A1HPGDKDM4E | |
| SCHEMBL9113884 | 0.78 | KMT2A (1.00) | KMT2AGAAALDH1A1HPGDKDM4E | |
| SCHEMBL5082541 | 0.78 | KMT2A (0.67) | KMT2AGAAALDH1A1HPGDKDM4E | |
| SCHEMBL7749862 | 0.77 | KMT2A (0.46) | KMT2AGAAALDH1A1HPGDLMNA | |
| SCHEMBL28509657 | 0.76 | ALDH1A1 (0.72) | KMT2AGAAALDH1A1HPGDKDM4E | |
| SCHEMBL4064682 | 0.75 | HPGD (0.59) | KMT2AALDH1A1HPGDKDM4EHTT | |
| SCHEMBL22412505 | 0.75 | CYP2C9 (0.49) | KMT2AGAAALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1415986-B1 | SPIRO ISOBENZOFURANES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | BANYU PHARMA CO LTD (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-7205417-B2 | Spiro compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| US-20040259890-A1 | Spiro compounds | MSD K.K. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1415986-A1 | SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259890-A1 | Spiro compounds | OPRD1, PER2, OPRK1 | KMT2A 1273/4885GAA 2357/4885ALDH1A1 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.